Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIEL showed 24.705 billion shares outstanding in the Q1 2022 Financials
BIEL showed 24.705 billion shares outstanding in the Q3 2022 Financials.
That is zero dilution in Q2 and again in Q3 2022.
St John's has made $91k in Interest Only Loans to BIEL in 2022.
Dr. Staelin has made $535k in Interest Only Loans to BIEL since he returned to the COB position in 2020.
Erin Sanders made a $25k Interest Only Loan to BIEL in Q3 2022.
IBEX and St John's have saved BIEL $2.5 million by foregoing the interest on their loans over the last several years.
Everyone at BIEL is serious about controlling dilution and bringing BIEL to profitability.
Looks like an arranged purchase
30 million shares purchased at 11:09 in 6 seconds at the 6 Ask with only a 10k Ask Size.
"Earlier this year" is a bit vague, provide a link, we are already half way through Q4
Sounds like someone wants to wait until news hits to Buy their shares
Cindy Asch-amputee trainer
11/12/2022
Do you suffer from Phantom Pain? This device is amazing! http://recoveryrx.co to request your evaluation kit.
@RecoveryRx #amputeelife #amputtee #phantompain #painrelief
@AmputeesUSA #amputeestrong
https://twitter.com/search?q=%23AmputeeStrong&src=hashtag_click
https://twitter.com/asch_cindy/status/1591498469151510528
So what is your theory as to why SAI, after releasing promotional material on 10 new 'Powered By ActiPatch' products in 3/2021, has not launched in the US yet?
Supply issues seems most logical to me. SAI wanted to launch 3/2021 but due to a shortage of Chips, which I have shown as disrupting Medical Device production, they had to delay their US launch. They did a small online launch in Canada this year which says to me that they still want to sell their 'Powered By ActiPatch' products if BIEL can provide enough devices.
Please provide an alternat theory given these facts.
https://halohealthcare.com/en-us/products/airway-surgical-otc-shoulder-wrap-with-actipatch-device
Well known Fact, Chip Shortage affected hundreds of products including Medical Devices
Five minutes on Google:
Medical Device Shortages During the COVID-19 Public Health Emergency
FDA statement
"The FDA publishes a device shortage list to provide transparency to the American public, particularly those who use or purchase medical devices. The list fulfills a statutory obligation under section 506J of the FD&C Act and reflects the categories of devices the FDA has determined to be in shortage at this time and will be maintained and updated as the COVID-19 public health emergency evolves. The presence of a device type on this list does not necessarily indicate that patient care has been affected."
https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/medical-device-shortages-during-covid-19-public-health-emergency
How is the semiconductor shortage affecting medtech?
Deloitte Posted: 28 Jun. 2022
"Semiconductors, and their integrated circuits, act as the brain for millions of products—from smartphones, to automobiles, to laptops, to medical devices. However, these once inexpensive and plentiful silicon chips have been in short supply for more than 18 months, and medical device companies are suddenly competing with virtually every other manufacturing sector for limited inventory. Many medtech manufacturers are making difficult decisions to help ensure they can continue to meet the needs of the market. Some of them are likely to implement new (and often more expensive) strategies to keep their production lines moving."
https://www2.deloitte.com/us/en/blog/health-care-blog/2022/how-is-the-semiconductor-shortage-affecting-medtech.html
How the Supply Chain Upheaval Became a Life-or-Death Threat
NYT 12/09/2021
"A maker of medical devices can’t keep up with customer demand as the shortage of computer chips puts it in competition with bigger companies with more clout."
"ResMed has struggled to buy enough chips, Mr. Farrell said, constraining its ability to make a range of vital equipment — from ventilators used by Covid patients to breathing devices that sustain premature infants."
"The company is “producing less than 75 percent of what our customers need,” Mr. Farrell said."
https://www.nytimes.com/2021/12/09/business/supply-chain-medical-device-shortages.html
Medtechs face supply chain disruptions from semiconductor shortage
"The global semiconductor chip shortage is causing delays, order cancellations and other supply disruptions at medtech companies, according to a study commissioned by AdvaMed."
"Deloitte, which conducted the survey, found all respondents have experienced some level of disruption to their chip supply chain, with delays ranging from two weeks to more than one year."
"Evidence of the impact on medtech emerged over the summer, when ResMed cited the shortage of semiconductors as a reason it will be unable to meet all the demand created by the recall of devices by its competitor Philips."
"ResMed CEO Mick Farrell said he is calling suppliers and saying: “Look, this component can go into a cell phone or a car, or it can go into a medical device that literally gives someone the gift of breath. Please prioritize our part of the supply chain.” "
Some did not see or did not comprehend the latest news on integrated circuits
post 301949 11/10/2022
For Chip Makers, the Flip From Shortage to Glut Intensifies
WSJ Nov. 4 2022
After sharp growth during Covid, semiconductor executives now are pausing hiring and cutting costs amid high inventory levels
The belt-tightening represents a turnabout after two heady years characterized by sky-high demand for computers, smartphones, cars and internet services that rely on chips. While the chip industry is notoriously cyclical, this wave rose higher and lasted longer than one has in decades, propelled by a pandemic that drove a societal shift toward working and learning from home.
“What has happened is that the macroeconomic environment deteriorated, and we went from a period of supply shortages to demand declines,” Akash Palkhiwala, Qualcomm’s chief financial officer, said in a call with analysts. “It’s an unprecedented change over a short period of time.”
https://www.wsj.com/articles/chip-makers-cut-costs-as-demand-slump-supplants-pandemics-chip-shortage-11667560050
Business 101, don't spend money creating demand for a product that you can't supply
No company starts an expensive advertising campaign for a product that its manufacturer may not be able to produce.
Shortly after KT launched the Wave SAI released cut sheets on its 10 new 'Powered By ActiPatch' products, March 2021. There was no launch in 2021. We had another SAI tease earlier this year but once again no US launch. We did get a small Canadian online launch through SAI's Canadian branch, Airway Surgical.
SAI was not going to launch 10 products into the US market while there were questions about the availability of the key component of these new products.
Now that the 'Chip Shortage' has turned into a 'Chip Glut' it would be great to see SAI enter the US 'Powered By ActiPatch' market.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162254341
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162084303
KT Tape had the following direct shipments from BIEL's factory:
12/2020 - 16 pallets, 3770 cartons, 8543 lbs
04/2021 - 20 pallets, 4332 cartons, 11384 lbs
06/2021 - 14 pallets, 2848 cartons, 7790 lbs
Those sales were the largest contributor to BIEL's Q4 2020 and Q2 2021 Revenue which totaled $934k.
This as a large investment by KT Tape in their new 'Wave' product.
KT does not take a "maybe it'll sell, maybe not, doesn't hurt us if it doesn't." attitude with this large of an investment.
IMO, KT shot themselves in the foot with the Wave launch by pricing it at $34.99 for a 250 hour product. They recently have tried to correct this mistake with a RRP price drop to $29.99 for a single unit and $23.99 for a subscription plan..
How can you compare a product with 206,000 potential customers to a product with 13 million potential customers?
Blepharoplasty procedures in the US each year 206,000
ActiBand FDA Clearance, For the treatment of edema following Blepharoplasty
Surgical procedures in the US each Year 13 million.
RecoveryRx FDA Clearance, Adjunctive treatment of postoperative pain
The Disinformation Has No End
<<<<<<<<<< False, biel failed in PSWT. ActiBand proved it in 2005 >>>>>>>>>>>
ActiBand was a Prescription Only 'ILX' product code device, FDA Cleared in 2002.
Pulsed Shortwave Therapy, PSWT, did not exist until the 2015 FDA Reclassification, creation of the PSWT description, and the 'PQY' Product Code which made OTC available to ActiPatch.
The Prescription Only ActiBand proved nothing about the Over the Counter PQY ActiPatch that was first FDA Cleared fifteen years later in 2017.
Great news for BIEL, Chips Ahoy
Due to a down turn in demand and China sanctions the global Chip Shortage is turning into a Chip Glut. BIEL will have access to all the semiconductors it needs, say 975,000, and will be able to buy them at a lower cost increasing margins.
For Chip Makers, the Flip From Shortage to Glut Intensifies
WSJ Nov. 4 2022
After sharp growth during Covid, semiconductor executives now are pausing hiring and cutting costs amid high inventory levels
The belt-tightening represents a turnabout after two heady years characterized by sky-high demand for computers, smartphones, cars and internet services that rely on chips. While the chip industry is notoriously cyclical, this wave rose higher and lasted longer than one has in decades, propelled by a pandemic that drove a societal shift toward working and learning from home.
“What has happened is that the macroeconomic environment deteriorated, and we went from a period of supply shortages to demand declines,” Akash Palkhiwala, Qualcomm’s chief financial officer, said in a call with analysts. “It’s an unprecedented change over a short period of time.”
https://www.wsj.com/articles/chip-makers-cut-costs-as-demand-slump-supplants-pandemics-chip-shortage-11667560050
Let's consider the sources on that issue
<<<<<<<<<< There IS NO signed agreement with Synergy >>>>>>>>>>>>
We have BIEL who stated in a Company Conference Call that there is a signed Deal for RecoveryRx jn 25 Countries with Synergy Corp..
We have a message board poster who says there is no Synergy Deal and has a disclaimer on all of their posts, 'Everything I say and write is my opinion and my opinion only'.
Didn't even notice that anyone was missing
Missed the whole 8/25 Conference Call.
Don't worry I'll fill ya in,
* We have signed a Deal for 25 Countries with Synergy Corp
* The signed agreement calls for 975,000 units of RecoveryRx to be purchased over the first 18 months
* Largest contract to date for BIEL
Oh well, back in time for the Synergy PR.
If we are talking US FDA 'Cleared' or 'Approved' OTC BIEL currently holds a monopoly
There are a few PEMF 'Wellness' devices, like the Oska $399 and the size of a computer mouse, that simply have to Register with the FDA and can make no claims of treating any medical conditions.
Oska has a great Einstein quote on their home page. I am surprised BIEL has not done something with it.
“Future medicine will be the medicine of frequencies.”
— Albert Einstein
Wow Hawk supplying 17 pharmacies, 1,000 employees
"In 1755, we founded our first pharmacy in the then capital, Turku, and in two centuries the small artisan workshop has grown into a company employing more than a thousand people, serving consumers and Finnish healthcare."
"The well-being of you and your loved ones is a matter of the heart for us. We serve 17 pharmacies, partner pharmaciesandonline stores all over Finland, and our customer experience is proven to be one of the best in Finland."
Thanks for the link InvestInBiel.
KT Wave still resides in the 'Pole Position' on the KT Recovery+ Amazon page
https://www.amazon.com/stores/page/61BED363-DAF3-4251-865C-0EF88333F743?ingress=2&visitId=212e1d46-19b3-42a9-9721-4dca1b62fc90&ref_=ast_bln
As a Fantasy company Sales-Track can project what ever Opinion the writer desires. Let me demonstrate, Sales-Track currently estimating sales jumping 90% for Q4.
The Synergy Deal was announced in a BIEL Conference Call:
"We have signed a Deal for 25 countries"
"The signed agreement calls for 975,000 units of RecoveryRx to be purchased over the first 18 months"
If you have evidence it is a "fake deal" you should advise the SEC.
Deeper dive may have been helpful as there are 7 different reports on the page 1 results. Some have similar information but if you have competent researchers studying the same subject they would agree on some aspects.
Pages 2-3 of the results have another 8 Reports including:
This statement about Covid from Data M Intelligence,
"The COVID-19 pandemic has boosted the growth of the PEMF therapy device market, as few studies are being published on using PEMF therapy devices for the prevention or treatment of COVID-19. PEMF therapy devices help positively charge body cells, which are beneficial in preventing cell clumping together due to the Rouleaux effect. It means that body cells can continue functioning as normal and are thus able to deliver oxygen throughout the body. It is helpful for the proper functioning of the immunity system to function properly, which is helpful in fighting Covid 19.
And this CAGR estimate from Data Intelo,
"The global pulsed electromagnetic field therapy devices sales market is expected to grow at a CAGR of 10.7% during the forecast period (2022-2030). This growth can be attributed to the increasing incidence of chronic diseases, rising demand for minimally invasive therapies, and growing awareness about the benefits of pulsed electromagnetic field therapy devices."
Page 1 Results:
Research and Markets - https://www.businesswire.com/news/home/20211229005191/en/Global-Pulse-Electromagnetic-Field-Therapy-Devices-Market-Set-to-Reach-USD-693.3-Million-by-2028-with-a-CAGR-of-7.8-During-2021-2058---ResearchAndMarkets.com
360 Research - https://www.marketwatch.com/press-release/pemf-therapy-device-market-competitive-landscape-and-analysis-by-recent-trends-2022-to-2028-119-pages-report-2022-11-03
Grandview Research - https://www.grandviewresearch.com/industry-analysis/pulse-electromagnetic-field-pemf-therapy-devices-market-report
QY Research - https://www.biospace.com/article/pulse-electromagnetic-field-pemf-therapy-devices-market-size-us-761-3-mn-by-2030/?keywords=ipo+
Stratview Research - https://www.stratviewresearch.com/1687/pulsed-electromagnetic-field-therapy-devices-market.html
Trasparancy Research - https://www.transparencymarketresearch.com/pulsed-electromagnetic-field-therapy-devices-market.htmlhttps://www.transparencymarketresearch.com/pulsed-electromagnetic-field-therapy-devices-market.html
FutureWise Research - https://www.futurewiseresearch.com/healthcare-market-research/Pulsed-Electromagnetic-Field/11356
Correct pinhigh , but actually it goes back 2,000 years.
Electric current to cure arthritis and cephalaea in ancient Greek medicine
Electricity in ancient Greece was a known phenomenon as well. Ancient Greeks attributed to god Zeus (Greek: ??a?), father of gods and men, the thunderbolt as the ultimate sacred weapon (Figure 1A).8,9 Ancient Greek philosophers had tried to understand amber's electromagnetic properties and thus to interpret the divine thunderbolts' mystery. Soon, electric currents had been used in medicine to treat arthritis and local swelling and pain, and cephalaea as well. The ancient Greeks used the electric shocks from the fish "Narce" (Greek: ?????, English: Torpedo fish), an Electric Ray fish, to treat headaches and arthritis
https://mjrheum.org/december-2016/newsid792/60/showfulltext792/1#:~:text=Hippocrates%2C%20Skivronios%20Largos%2C%20Pliny%20and%20Dioscorides,physical%20medicine%20by%20the%20ancient%20Greeks.&text=Hippocrates%2C%20Skivronios%20Largos%2C%20Pliny,by%20the%20ancient%20Greeks.&text=Largos%2C%20Pliny%20and%20Dioscorides,physical%20medicine%20by%20the
Nope, that's just an Opinion
The same Fantasy Opinions that have been dumped on this Board every day for the last 10 years.
'the most ridiculous company and waste of effort I've seen' 9/9/2012
'FDA doesn't want to be preceived as "SNAKE OIL" approvers' 9/11/2012
'A very well orchestrated organized scam' 9/12/2012
'they can't in their screwed up bogus trials prove anything' 9/13/2012
I will go with the FDA's Opinions:
FDA Clearance #K192234 Musculoskeletal Pain
FDA Clearance #K152432 Plantar Fasciitis / Osteoarthritis
FDA Clearance #K190251 Postoperative Pain
'
This is not the Official KT Tape Site on Amazon
This is one reseller of KT products on Amazon,
"Sold by Scharf Industries LLC"
The 'Seller' of products on Amazon is the one who designates the 'Category' for their product page.
The Official KT Tape Amazon Site still does not have a category for the Wave designated.
https://www.amazon.com/KT-Tape-Recovery-Electromagnetic-Relief/dp/B08WTN6V2Y?ref_=ast_sto_dp
No Painting Today, 9 Million Share Buy at 3:59:28
There were 8,837,601 shares on the 7 Ask when this 9 million share Buy order hit.
The MMs filled the order in 4 seconds with 5 Trades.
The last Trade required a move up to 8 as the 7s were all gone.
Go BIEL !!!
Must be looking at the wrong Stock, No PR yet on Synergy Deal
Synergy Deal stated in Conference Call.
PR to be released when the initial order is received.
KT Wave moves up to #69 on Amazon.
"#69 in Muscle Stimulators & Accessories"
The Synergy Deal was announced in a BIEL Conference Call by the VP of Sales and BIEL BOD member, it is very "Real"
This type of announcement carries much more weight and much more serious consequences for false statements than a Tweet.
Printed copy of the Synergy Deal can be viewed here,
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169830850
Got eyes on the wrong event
'I can see it already', Synergy's opening order makes Q4 2022 the largest Quarterly Revenue in BIEL's History with 5 more Quarters to come in the 975,000 unit signed contract.
Q3 revenue becomes irrelevant.
A Load of BS, Can't blame a CEO for the mistakes and say they had nothing to do with the successes, the Buck Stops on the CEO's Desk
"Kelly Whelan didn't have anything to do with getting FDA clearance."
KW took over BIEL in October 2019. The Musculoskeletal FDA Clearance was not granted until February 2020, You have No knowledge of KW's involvement in getting the FDA to approve this Clearance.
"Kelly Whelan didn't find any deals to have the product marketed - Nalepka and Staelin did all that."
First, Dr. Staelin did not rejoin BIEL until June 2020. KW made the decision to move to the OEM Business Plan which brought in the KT Tape Deal 12/2020, the DJO/Scott Deal 11/2020, the SAI/Airway Deal 3/2021, the CE Mark which opened the 440 million person EU Market. Once again you have No knowledge of KW's involvement in these deals which is also true for the Synergy Deal in Asia/MENA, 'Novro Med S.A. de C.V' Deal in Mexico, the Prim Group Deal in Spain, the Adcock Ingram Deal in S. Africa.
"Regardless, my post was about her qualifications to BECOME CEO - as in, what did she do before becoming CEO that qualifies her to run a publicly traded company?"
The Whelan Family, KW through IBEX & PW through St John's, own a controlling interest in BIEL via their $9.2 million in outstanding Loans. Add in Dr. Staelin's $857k in Loans and we clear $10 million. That is what gives the Whelans the right to say who heads the company. This is also why we had a relentless campaign in 2019 - 2020 for IBEX to forfeit the rights to 17 billion shares. with those shares gone a group of investors could pool their shares and take control of BIEL.
Whether one approves or disapproves of KW's decisions as CEO I will take her commitment to making the company that her father founded successful verses any corporate raiders wanting to take over BIEL.
No, BIEL has been in Business close to 20 years now, the 11 years is the number of years that some have been predicting that BIEL would cease operations.
Quite a record, 11 Losses and Zero Wins.
When a company finances operations by selling shares in the company dilution will occur. A company can raise the Authorized Shares to accommodate this type of financing or a company can perform Reverse Splits which masks the dilution.
BIEL chose to increase the AS.
Our friends at Endonovo, also in the medical device business, ENDV, chose the RS path. A 1 for 100 RS in 2014, that one million shares you owned was now 10,000 shares. In 2019 ENDV did another RS this time 1 for 1,000. That 10,000 shares you owned was now 10 shares.
That $200,000 investment you made in 2014 is now worth less than $8 with ENDV currently selling for .0078. And they will need another RS soon to keep their OTCQB status which requires a 1 cent minimum stock price.
Using ENDV again for a Sales gauge:
ENDV - 2021 - $73k, 2020 - $165k
BIEL - 2021 - 1.6 million, 2020 - $829k
https://ir.endonovo.com/press-releases/detail/134/endonovo-therapeutics-affects-1-for-100-reverse-stock-split
https://www.globenewswire.com/news-release/2019/12/11/1959453/0/en/Endonovo-Therapeutics-Announces-Reverse-Stock-Split.html
Been saying the same thing every year for 11 years and yet BIEL is still in business
Good Grief, wrong 11 years in a row and going for 12.
Neglected to include an important statistic
8.2 million shares Naked Shorted today.
FINRA Reg SHO Daily Short Volume
Date .. Symbol . Short Vol.... Total Vol.
20221026|BIEL|8228998 |||||||10619543
Technology to Change Your Future
Drug Free
Odor Free
Sensation Free
#Neuromodulation
https://twitter.com/search?q=%23neuromodulation
https://twitter.com/BielCorp/status/1584577545261174784/photo/1
Time to recognize BIEL as a Neuromodulation Company not just a Pain Relief Company.
Neuromodulation is technology that acts directly upon nerves. It is the alteration—or modulation—of nerve activity by delivering electrical or pharmaceutical agents directly to a target area.
Neuromodulation devices and treatments are life changing. They affect every area of the body and treat nearly every disease or symptom from headaches to tremors to spinal cord damage to urinary incontinence. With such a broad therapeutic scope, and significant ongoing improvements in biotechnology, it is not surprising that neuromodulation is poised as a major growth industry for the next decade.
Most frequently, people think of neuromodulation in the context of chronic pain relief, the most common indication. However, there are a plethora of neuromodulation applications, such as deep brain stimulation (DBS) treatment for Parkinson's disease, sacral nerve stimulation for pelvic disorders and incontinence, and spinal cord stimulation for ischemic disorders (angina, peripheral vascular disease).
In addition, neuromodulation devices can stimulate a response where there was previously none, as in the case of a cochlear implant restoring hearing in a deaf patient.
Several Very Large Holes in that Opinion
Convertible Note Holders have to Convert their Loans to Shares before they can Sell
BIEL has only 295 million shares available to pay back Convertible Note Holders with before they hit their 'Authorized Share' limit
All of BIEL's current Convertible Loans are with 'Friendly Lenders' who have rolled over their Loans in the past, IBEX, St John's, Dr Staelin, T. Kim, Jarman
Since Dr Staelin rejoined BIEL as COB in 2020 all of his many Loans to BIEL have been Principle & Interest only, No Conversion option
St John's also switched to Principle & Interest Loans in January 2022
Not paying attention, 19.9 million shares on the Buy side today made the move to 8 possible vs 70k on the Sell side
99.65 percent of today's transactions were Buys. That is a change in investor sentiment well worth noting.
LOL BIEL up 23%, Yes stay on the bench and watch BIEL head back into the double zeros, that is the "Smart" thing to do.
1 million shares at 8 just got purchased.
More Buys, 10 Million Shares at 1:27 Ups BIEL to an 8 Ask
Buys = 18.7 million
Sell = 70k
Go BIEL !!!
Very Nice Buy 8.5 Million Shares at 12:16
Go BIEL !!!
This conversation got me thinking about Bioboosti, something found several years ago, PEMF based device in China that partnered with insurance companies. Biomobie Company founder Jack Wang proved to clients that his PEMF device, Bioboosti, worked and negotiated an efficient way to sell millions of devices.
"Instead of going through the hospitalization route, which is a bit complicated, we decided to go down the preventative route."
"We, therefore, decided to approach insurance companies to finance the device’s use, and this business model started in 2019. As our device can both alleviate chronic conditions and prevent them, insurance companies can potentially save millions of dollars. We have already signed contracts with major insurance companies like PingAn Insurance, Taiping Insurance and Taikang Insurance. Whereas before insurance companies might refuse to sell insurance to people with high blood pressure or other pre-existing conditions, they will now sell a bundled insurance package under the condition that they use Bioboosti every day, and the usage will be monitored through an app."
"The corporate world is also interested in this idea to manage the health of their employees. One of the largest Chinese banks is going to be covering its 300,000 employees with such a bundled insurance package. Not all of them are going to be using Bioboosti, only the ones at risk – and when they use it, their rates will go down."
The Bioboosti is a more sophisticated PEMF device than ActiPatch but the principle of PEMF use lowering healthcare costs, as Dr. Staelin showed in his UK Study, is similar.
https://pharmaboardroom.com/interviews/jack-wang-founder-ceo-biomobie-china/
http://en.biomobie.com/principle.htm
Yep pinhigh, a logical first step
If the patient has no insurance or high deductibles it makes even more sense as implant devices can run $50k, there is always a possibility of surgery complications and if the device fails another surgery is needed.
Yep GG, Setpoint uses an iPad to control the specifics of therapy dictated by a prescription
The implant has to be recharged daily via a contactless charging collar.
Setpoint was established in 2007 to develop this device so they have been at it for 15 years.
$30 Million for Trials, Bioelectronic Device in Rheumatoid Arthritis
SetPoint Medical rounded up $30 million in its series D round, which will drive the clinical development of its bioelectronic treatments for chronic, inflammatory illnesses and bankroll a phase 2 trial of a bioelelectronic device in rheumatoid arthritis.
"Existing investors, including New Enterprise Associates, GlaxoSmithKline, Boston Scientific and Medtronic, participated in the financing. Valencia, California-based SetPoint previously raised $15 million in series C funding.
Bioelectronic therapies, based on implantable devices that stimulate the body to heal itself from disease, are increasingly being looked to as alternative treatments for inflammatory diseases, which often have limited treatment options.
SetPoint’s bioelectronic platform is designed to stimulate the body’s natural Inflammatory Reflex and trigger an anti-inflammatory effect, the company says. Bioelectronics could be used to elicit biochemical changes in the body that are typically brought about by drugs.
***************************************************
How about an Anti-Inflammatory Bioelectronic Device that does not require Implant Surgery.
https://www.fiercebiotech.com/medtech/setpoint-medical-nabs-30m-for-bioelectronics-rheumatoid-arthritis-trial